Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Zai Lab LimitedNASDAQ: ZLAB

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables dips below year-ago levels

Q2 FY2026 accounts receivables of $10.96M (cash outflow) fell 4.0% year over year, behind the +212.9% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 6.5% of revenue in FY2025, down 0.1 pp from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -4.0% toward the trailing-twelve-month pace of +212.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$10.96M-119.0% QoQ
Last fiscal yearDec 2025
-$29.98M+12.8% YoY
LTMJun 2026
$26.3M+212.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-4.0%——
1 year+12.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(29.98M) USD
Year-over-year change
-12.8%

Accounts Receivables vs competitors

How ZLAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +212.9% is the highest of 3, against a peer median of -118.7%.
  • Accounts receivables amounts to 5.8% of revenue for ZLAB, versus a peer median of 1.6%.
ZLAB Competitors
Accounts Receivables for ZLAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAPGAscentage Pharma Group InternationalFY2025CN¥169.8M CNY-370.6%+659.2%30.4%
ZLABZai Lab LimitedLTM Jun 2026$26.3M USD+212.9%—5.8%
HCMHUTCHMED (China) LimitedLTM Jun 2025$9.93M USD+133.2%—1.6%
ANLAdlai Nortye Ltd.LTM Jun 2024$0 USD——0.0%
Peer median (excluding ZLAB) —-118.7%+659.2%1.6%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
Deferred Income Tax17.08M0000
Stock-Based Compensation40.71M61.3M79.63M70.65M65.6M
Change in Working Capital23.11M(66.25M)39.61M(68.39M)(54.71M)
Accounts Receivables(42.32M)25.14M(17.69M)(26.58M)(29.98M)
Inventory(7.17M)(15.38M)(14.91M)3.9M(47.03M)
Accounts Payables63.52M(53.77M)36.8M(2.21M)19.93M
Other Working Capital9.08M(22.23M)35.4M(43.5M)2.38M
Other Non-Cash Items67.85M72.36M8.17M28.12M(1.15M)
Operating Cash Flow(549.23M)(367.64M)(198.18M)(214.87M)(150.79M)
Capital Expenditures(18.95M)(24.98M)(8.49M)(61.52M)(13.42M)
Acquisitions (Net)(30M)0029K0
Purchases of Investments(445M)(260.27M)(134M)(330M)(10M)
Sales of Investments743.9M705.27M117.7M16.3M331.2M
Other Investing Activities3K(399K)12.74M(55.86M)(5.24M)
Investing Cash Flow249.96M420.02M(10.78M)(375.19M)307.87M
Debt Repayment000131.32M67.94M
Common Stock Issued818.88M00217.35M13.68M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.33M(1.73M)(6.43M)1.22M(9.27M)
Financing Cash Flow820.2M(1.73M)(6.43M)349.89M72.35M
Effect of Forex Changes1.12M(6.27M)(2.62M)(310K)478K
Net Change in Cash522.04M44.37M(218.01M)(240.48M)229.91M
Free Cash Flow(568.18M)(392.63M)(206.67M)(276.39M)(164.21M)

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.